[go: up one dir, main page]

AR074924A2 - Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas - Google Patents

Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas

Info

Publication number
AR074924A2
AR074924A2 ARP090105137A ARP090105137A AR074924A2 AR 074924 A2 AR074924 A2 AR 074924A2 AR P090105137 A ARP090105137 A AR P090105137A AR P090105137 A ARP090105137 A AR P090105137A AR 074924 A2 AR074924 A2 AR 074924A2
Authority
AR
Argentina
Prior art keywords
peptides
pharmaceutical compositions
hsp60
apl
binding peptide
Prior art date
Application number
ARP090105137A
Other languages
English (en)
Inventor
Horta Maria Del Carmen Dominguez
Palomares Gabriel Ramon Padron
Alba Jose Suarez
Diaz Carelia Cosme
Marin Nelia Lopez
Perez Norailys Lorenzo
Betancourt Ariana Barbera
Garcia Ariadna Hernandez
Cordova Vivian Morera
Garcia Nelson J Merino
Bonachea Ariel Vazquez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR074924A2 publication Critical patent/AR074924A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La solicitud también refiere a composiciones farmacéuticas que comprenden tales péptidos para tratamiento de la artritis reumatoide. Reivindicación 1: Un péptido de la proteína humana de estrés térmico de 60 kDa que constituye epítope para células T, para inducir mecanismos de tolerancia periférica, en particular mecanismos inductores de anergia o mediados por clones de células T regulatorias en pacientes con AR caracterizado porque presenta la secuencia E18-12 MGPKGRTVIIEQSWGSPKVTK (SEQ. ID. Ns:1).
ARP090105137A 2004-09-24 2009-12-28 Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas AR074924A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Publications (1)

Publication Number Publication Date
AR074924A2 true AR074924A2 (es) 2011-02-23

Family

ID=40273413

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103950A AR051928A1 (es) 2004-09-24 2005-09-21 Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
ARP090105137A AR074924A2 (es) 2004-09-24 2009-12-28 Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050103950A AR051928A1 (es) 2004-09-24 2005-09-21 Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas

Country Status (17)

Country Link
US (2) US8383771B2 (es)
EP (2) EP2371847B1 (es)
JP (1) JP4755649B2 (es)
KR (2) KR101035283B1 (es)
CN (2) CN101065398B (es)
AR (2) AR051928A1 (es)
AT (1) ATE546462T1 (es)
AU (2) AU2005287757B2 (es)
BR (2) BRPI0515893B8 (es)
CA (2) CA2581110C (es)
CU (1) CU23504A1 (es)
DK (2) DK2371847T3 (es)
ES (2) ES2445707T3 (es)
MX (1) MX2007003624A (es)
RU (1) RU2361877C2 (es)
WO (1) WO2006032216A2 (es)
ZA (1) ZA200702938B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034396C (en) 2007-01-30 2022-08-02 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
CN102740877B (zh) * 2009-09-06 2015-01-14 普罗塔布有限公司 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途
WO2011059758A2 (en) * 2009-10-28 2011-05-19 Argentis Pharmaceuticals, Llc Apls for treating arthritis
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
KR102333645B1 (ko) 2021-07-27 2021-12-02 (주)문화전기 각도조절이 용이한 엘이디조명시스템
CN115671253B (zh) * 2021-07-30 2024-02-27 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
GB9419553D0 (en) 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
GB9519737D0 (en) * 1995-09-27 1995-11-29 Peptide Therapeutics Ltd Polypeptides and their use in treatment and prophylaxis of auto-immune
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
GB9911772D0 (en) 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
US20020169302A1 (en) * 1999-08-23 2002-11-14 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
EP1237570A4 (en) * 1999-12-15 2005-01-05 Peptor Ltd FRAGMENTS AND ANTAGONISTS OF THERMAL SHOCK PROTEINS 60
AU2002247004A1 (en) 2001-01-19 2002-07-30 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis

Also Published As

Publication number Publication date
EP1803732B1 (en) 2012-02-22
CA2797769C (en) 2015-09-15
AR051928A1 (es) 2007-02-21
CN101935345B (zh) 2013-12-11
CU23504A1 (es) 2010-04-13
EP1803732A2 (en) 2007-07-04
ATE546462T1 (de) 2012-03-15
DK1803732T3 (da) 2012-05-29
EP2371847B1 (en) 2013-11-20
ZA200702938B (en) 2008-08-27
JP4755649B2 (ja) 2011-08-24
BR122018077204B1 (pt) 2020-01-28
CA2797769A1 (en) 2006-03-30
JP2008514553A (ja) 2008-05-08
DK2371847T3 (da) 2014-02-03
BR122018077204B8 (pt) 2021-07-27
KR20070073787A (ko) 2007-07-10
AU2010219312B2 (en) 2011-10-06
US8324164B2 (en) 2012-12-04
WO2006032216A2 (es) 2006-03-30
BRPI0515893A (pt) 2008-08-12
KR101054332B1 (ko) 2011-08-04
KR101035283B1 (ko) 2011-05-18
BRPI0515893A8 (pt) 2019-01-02
EP2371847A1 (en) 2011-10-05
AU2005287757A1 (en) 2006-03-30
ES2386498T3 (es) 2012-08-22
BRPI0515893B8 (pt) 2021-05-25
AU2010219312A1 (en) 2010-09-23
CN101065398B (zh) 2012-12-19
CN101065398A (zh) 2007-10-31
CA2581110A1 (en) 2006-03-30
CA2581110C (en) 2013-04-02
RU2007115411A (ru) 2008-10-27
CN101935345A (zh) 2011-01-05
RU2361877C2 (ru) 2009-07-20
BRPI0515893B1 (pt) 2020-09-15
US8383771B2 (en) 2013-02-26
KR20100028645A (ko) 2010-03-12
MX2007003624A (es) 2007-06-13
WO2006032216A3 (es) 2007-05-18
ES2445707T3 (es) 2014-03-04
AU2005287757B2 (en) 2010-07-29
US20100144642A1 (en) 2010-06-10
US20090171069A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
AR074924A2 (es) Peptidos y derivados tipo peptido ligando alterado (apl) de la hsp60 y composiciones farmaceuticas
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
RU2013128895A (ru) Улучшенные n-терминальные кэппинг модули для сконструированных белков с анкириновым повтором
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
AR065611A1 (es) Polipeptidos del receptor de activina variante y usos de los mismos
CY1113117T1 (el) Ηlα-α*3303-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση η οποια περιλαμβανει αυτο το ιδιο
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
MX385794B (es) Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
WO2008113970A3 (en) Peptides
EP2481748A3 (en) Foxp3 peptide vaccine
WO2014111841A3 (en) Peptide
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
GB201018125D0 (en) Peptide
DK1913020T3 (da) Immunogene konstrukter
MX2015016560A (es) Proteina analgesica aislada de la secrecion de la rana trachycephalous venulosus.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
ATE544779T1 (de) Neue, die migration dendritischer zellen induzierende polypeptide, sowie medikamente und pharmazeutische zusammensetzungen, die diese enthalten
WO2008029138A3 (en) Peptides and methods

Legal Events

Date Code Title Description
FG Grant, registration